EP2011514B1
(de)
|
1997-03-21 |
2012-02-29 |
Chugai Seiyaku Kabushiki Kaisha |
Präventives oder therapeutisches Mittel mit einem IL-6-Antagonisten als Wirkstoff für durch sensibilisierte T-Zellen vermittelte Erkrankungen
|
DE69942782D1
(de)
|
1998-11-27 |
2010-10-28 |
Ucb Sa |
Zusammensetzungen und Verfahren zur Erhöhung der Knochenmineralisierung
|
NZ535205A
(en)
*
|
1999-10-04 |
2006-01-27 |
Chiron Corp |
Stabilized liquid interleukin-2 ( IL-2 ) containing pharmaceutical compositions
|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
PT1324776E
(pt)
*
|
2000-10-12 |
2009-12-23 |
Genentech Inc |
Formulações de proteína concentradas de viscosidade reduzida
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
DK1401498T3
(da)
*
|
2001-05-30 |
2011-11-21 |
Genentech Inc |
Anti-NGF-antistoffer til behandlingen af forskellige sygdomme
|
GB0113179D0
(en)
*
|
2001-05-31 |
2001-07-25 |
Novartis Ag |
Organic compounds
|
AU2006202688B2
(en)
*
|
2001-05-31 |
2009-01-22 |
Genentech, Inc. |
Stable liquid formulations of antibodies
|
US20080026068A1
(en)
*
|
2001-08-16 |
2008-01-31 |
Baxter Healthcare S.A. |
Pulmonary delivery of spherical insulin microparticles
|
US20030138417A1
(en)
*
|
2001-11-08 |
2003-07-24 |
Kaisheva Elizabet A. |
Stable liquid pharmaceutical formulation of IgG antibodies
|
PL210412B1
(pl)
|
2002-05-24 |
2012-01-31 |
Schering Corp |
Izolowane przeciwciało anty-IGFR lub jego fragment, kompozycja farmaceutyczna, zastosowanie, kwas nukleinowy, zrekombinowany wektor, komórka gospodarza, kompleks, polipeptyd i sposób jego wytwarzania
|
US7425618B2
(en)
*
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US20040002451A1
(en)
|
2002-06-20 |
2004-01-01 |
Bruce Kerwin |
Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
|
AU2003251592A1
(en)
*
|
2002-06-21 |
2004-01-06 |
Biogen Idec Inc. |
Buffered formulations for concentrating antibodies and methods of use thereof
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
MY150740A
(en)
*
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
WO2004055164A2
(en)
*
|
2002-12-13 |
2004-07-01 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
WO2004060343A1
(en)
*
|
2002-12-31 |
2004-07-22 |
Nektar Therapeutics |
Antibody-containing particles and compositions
|
EP1599222B1
(de)
*
|
2003-01-08 |
2009-03-04 |
Novartis Vaccines and Diagnostics, Inc. |
Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
|
US20040208870A1
(en)
*
|
2003-01-30 |
2004-10-21 |
Medimmune, Inc. |
Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
|
PT1610820E
(pt)
*
|
2003-04-04 |
2010-12-16 |
Novartis Ag |
Formulações de elevada concentração de anticorpos e proteínas
|
US20050158303A1
(en)
*
|
2003-04-04 |
2005-07-21 |
Genentech, Inc. |
Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
NZ544618A
(en)
|
2003-06-16 |
2009-02-28 |
Celltech R & D Inc |
Antibodies specific for sclerostin and methods for increasing bone mineralization
|
KR20120098932A
(ko)
*
|
2003-06-27 |
2012-09-05 |
암젠 프레몬트 인코포레이티드 |
상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
|
DE10348550A1
(de)
*
|
2003-10-20 |
2005-06-16 |
Hexal Biotech Forschungsgmbh |
Stabile wässrige G-CSF-haltige Zusammensetzungen
|
EP1682184B1
(de)
*
|
2003-11-04 |
2013-10-16 |
LEK Pharmaceuticals d.d. |
Stabile pharmazeutische zubereitungen enthaltend granulozyten-kolonie stimulierungsfaktor
|
US20050136055A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
US20070184050A1
(en)
*
|
2003-12-25 |
2007-08-09 |
Kirin Beer Kabushiki Kaisha |
Stable water-based medicinal preparation containing antibody
|
WO2005072772A1
(en)
*
|
2004-01-30 |
2005-08-11 |
Suomen Punainen Risti Veripalvelu |
Pharmaceutical compositions
|
EP1765294B1
(de)
*
|
2004-05-12 |
2008-09-24 |
Baxter International Inc. |
Nukleinsäure-mikrokügelchen, ihre herstellung und abgabe
|
US8728525B2
(en)
*
|
2004-05-12 |
2014-05-20 |
Baxter International Inc. |
Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
|
MXPA06012992A
(es)
*
|
2004-05-12 |
2007-02-12 |
Baxter Int |
Microesferas que comprenden proteina y que muestran inyectabilidad en altas concentraciones de este agente.
|
PT1758558E
(pt)
*
|
2004-05-12 |
2013-12-05 |
Baxter Healthcare Sa |
Microesferas contendo oligonucleótidos, sua utilização para o fabrico de um medicamento para o tratamento de diabetes do tipo 1
|
MX2007000891A
(es)
*
|
2004-07-23 |
2007-04-18 |
Genentech Inc |
Cristalizacion de anticuerpos o fragmentos de ellos.
|
US7772182B2
(en)
*
|
2004-08-05 |
2010-08-10 |
Alza Corporation |
Stable suspension formulations of erythropoietin receptor agonists
|
US20060029551A1
(en)
*
|
2004-08-05 |
2006-02-09 |
Kui Liu |
Stable particle formulations of erythropoietin receptor agonists
|
TW200621282A
(en)
*
|
2004-08-13 |
2006-07-01 |
Wyeth Corp |
Stabilizing formulations
|
US7655758B2
(en)
|
2004-08-17 |
2010-02-02 |
Regeneron Pharmaceuticals, Inc. |
Stable liquid IL-1 antagonist formulations
|
US7572893B2
(en)
*
|
2004-08-17 |
2009-08-11 |
Regeneron Pharmaceuticals, Inc. |
IL-1 antagonist formulations
|
US20060051347A1
(en)
*
|
2004-09-09 |
2006-03-09 |
Winter Charles M |
Process for concentration of antibodies and therapeutic products thereof
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
HUE034109T2
(en)
*
|
2005-03-25 |
2018-01-29 |
Regeneron Pharma |
VEGF antagonist formulations
|
JP5620626B2
(ja)
|
2005-03-31 |
2014-11-05 |
中外製薬株式会社 |
会合制御によるポリペプチド製造方法
|
MX2007012896A
(es)
*
|
2005-04-15 |
2007-12-10 |
Schering Corp |
Metodos y composiciones para tratamiento o prevencion de cancer.
|
US7592429B2
(en)
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
MX2007014148A
(es)
|
2005-05-19 |
2008-01-11 |
Amgen Inc |
Composiciones y metodos para incrementar la estabilidad de anticuerpos.
|
WO2006138181A2
(en)
|
2005-06-14 |
2006-12-28 |
Amgen Inc. |
Self-buffering protein formulations
|
CN101351190B
(zh)
*
|
2005-11-01 |
2013-01-02 |
惠氏公司 |
用于药物重构或稀释的氯化钠溶液
|
US9309316B2
(en)
|
2005-12-20 |
2016-04-12 |
Bristol-Myers Squibb Company |
Stable subcutaneous protein formulations and uses thereof
|
EP1962907A2
(de)
*
|
2005-12-21 |
2008-09-03 |
Wyeth a Corporation of the State of Delaware |
Proteinformulierungen mit verminderter viskosität und anwendungen davon
|
EP1977763A4
(de)
*
|
2005-12-28 |
2010-06-02 |
Chugai Pharmaceutical Co Ltd |
Antikörper-enthaltende stabilisierende zubereitung
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
EP1988922A4
(de)
*
|
2006-02-03 |
2010-06-02 |
Medimmune Llc |
Proteinformulierungen
|
EP2009101B1
(de)
|
2006-03-31 |
2017-10-25 |
Chugai Seiyaku Kabushiki Kaisha |
Antikörpermodifikationsverfahren für die aufreinigung eines bispezifischen antikörpers
|
CA2647846C
(en)
|
2006-03-31 |
2016-06-21 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
US20080003220A1
(en)
*
|
2006-04-21 |
2008-01-03 |
Amgen, Inc. |
Buffering agents for biopharmaceutical formulations
|
US7608261B2
(en)
|
2006-06-16 |
2009-10-27 |
Regeneron Pharmacuticals, Inc. |
VEGF antagonist formulations suitable for intravitreal administration
|
US7964574B2
(en)
|
2006-08-04 |
2011-06-21 |
Baxter International Inc. |
Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
|
AU2007309616B2
(en)
|
2006-10-20 |
2011-10-06 |
Amgen Inc. |
Stable polypeptide formulations
|
CA2667989A1
(en)
*
|
2006-11-07 |
2008-11-06 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
US20100136028A1
(en)
*
|
2006-11-07 |
2010-06-03 |
Sparrow Carl P |
Antagonists of pcsk9
|
CN101600457B
(zh)
*
|
2007-01-09 |
2014-01-08 |
惠氏公司 |
抗il-13抗体调配物和其用途
|
UA96473C2
(ru)
*
|
2007-03-22 |
2011-11-10 |
Имклоун Ллк |
Жидкая стойкая композиция, которая содержит антитело imc-а12
|
WO2008118970A2
(en)
|
2007-03-27 |
2008-10-02 |
Sea Lane Biotechnologies, Llc |
Constructs and libraries comprising antibody surrogate light chain sequences
|
NZ580379A
(en)
|
2007-03-29 |
2012-10-26 |
Abbott Lab |
Crystalline anti-human il-12 antibodies
|
CA2682170A1
(en)
*
|
2007-03-30 |
2008-10-09 |
Medimmune, Llc |
Antibodies with decreased deamidation profiles
|
US8808747B2
(en)
*
|
2007-04-17 |
2014-08-19 |
Baxter International Inc. |
Nucleic acid microparticles for pulmonary delivery
|
CN101674805A
(zh)
|
2007-05-02 |
2010-03-17 |
诺沃-诺迪斯克保健股份有限公司 |
包括芳香族防腐剂和抗氧化剂的高浓度因子ⅶ多肽制剂
|
EP2144624A1
(de)
*
|
2007-05-15 |
2010-01-20 |
Stryker Corporation |
Konzentrierte proteinpräparate aus knochenmorphogenetischen proteinen und verfahren zu ihrer verwendung
|
US9493548B2
(en)
|
2007-06-01 |
2016-11-15 |
Hoffmann-La Roche Inc. |
Immunoglobulin purification
|
JOP20080381B1
(ar)
*
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
CL2008002775A1
(es)
|
2007-09-17 |
2008-11-07 |
Amgen Inc |
Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
|
EP4339294A2
(de)
|
2007-09-26 |
2024-03-20 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur modifizierung eines isoelektrischen punkts eines antikörpers durch aminosäuresubstitution in cdr
|
CN105168123B
(zh)
*
|
2007-11-12 |
2019-03-08 |
阿雷斯贸易股份有限公司 |
Taci-免疫球蛋白融合蛋白制剂
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
EP3936116A1
(de)
|
2007-12-28 |
2022-01-12 |
Takeda Pharmaceutical Company Limited |
Rekombinanten vwf enthaltende formulierungen
|
US11197916B2
(en)
|
2007-12-28 |
2021-12-14 |
Takeda Pharmaceutical Company Limited |
Lyophilized recombinant VWF formulations
|
AR070315A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Anticuerpos 1b20 antagonistas de pcsk9
|
AR070316A1
(es)
*
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
|
WO2009141433A1
(en)
*
|
2008-05-23 |
2009-11-26 |
Novo Nordisk Health Care Ag |
Low viscosity compositions comprising a pegylated gla-domain containing protein
|
US20110104142A1
(en)
*
|
2008-05-23 |
2011-05-05 |
Novo Nordisk Health Care Ag |
Formulations of peg-functionalised serine proteases with high concentrations of an aromatic preservative
|
KR20110039218A
(ko)
*
|
2008-06-30 |
2011-04-15 |
노보 노르디스크 에이/에스 |
항-인간 인터루킨-20 항체
|
TWI670072B
(zh)
*
|
2008-10-21 |
2019-09-01 |
美商巴克斯歐塔公司 |
凍乾的重組vwf調配物
|
JP2012510468A
(ja)
*
|
2008-11-28 |
2012-05-10 |
アボット・ラボラトリーズ |
安定な抗体組成物およびこれを安定させるための方法
|
JP2012511586A
(ja)
|
2008-12-10 |
2012-05-24 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
医薬組成物
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
US10005830B2
(en)
|
2009-03-05 |
2018-06-26 |
Ablynx N.V. |
Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
US9265834B2
(en)
|
2009-03-05 |
2016-02-23 |
Ablynx N.V. |
Stable formulations of polypeptides and uses thereof
|
AR076640A1
(es)
*
|
2009-03-06 |
2011-06-29 |
Genentech Inc |
Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura
|
SG175188A1
(en)
*
|
2009-05-04 |
2011-11-28 |
Abbott Biotech Ltd |
Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
|
US20120128671A1
(en)
|
2009-05-13 |
2012-05-24 |
Lawrence Horowitz |
Neutralizing molecules to influenza viruses
|
WO2011002853A2
(en)
*
|
2009-07-01 |
2011-01-06 |
Fresenius Medical Care Holdings, Inc. |
Drug delivery devices and related systems and methods
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
AU2010279569A1
(en)
*
|
2009-08-04 |
2012-03-01 |
Genentech, Inc. |
Concentrated polypeptide formulations with reduced viscosity
|
US8221753B2
(en)
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
US8454956B2
(en)
*
|
2009-08-31 |
2013-06-04 |
National Cheng Kung University |
Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
|
EP3438126B1
(de)
|
2009-09-03 |
2020-08-19 |
Ablynx N.V. |
Stabile formulierungen aus polypeptiden und verwendungen davon
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
MX2012004682A
(es)
*
|
2009-10-26 |
2012-09-07 |
Hoffmann La Roche |
Metodo para la produccion de una inmunoglobulina glicosilada.
|
KR101832510B1
(ko)
*
|
2009-10-26 |
2018-02-26 |
제넨테크, 인크. |
치료 항-ige 항체에 대해 특이적인 항체를 검출하기 위한 검정 및 아나필락시스에서의 이의 용도
|
WO2011104381A2
(en)
*
|
2010-02-26 |
2011-09-01 |
Novo Nordisk A/S |
Stable antibody containing compositions
|
MX347504B
(es)
|
2010-03-01 |
2017-04-28 |
Cytodyn Inc |
Formulaciones concentradas de proteina y usos de las mismas.
|
LT2542257T
(lt)
|
2010-03-01 |
2017-11-27 |
Bayer Healthcare Llc |
Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi)
|
US9072668B2
(en)
|
2010-03-09 |
2015-07-07 |
Janssen Biotech, Inc. |
Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
|
US20110223208A1
(en)
|
2010-03-09 |
2011-09-15 |
Beth Hill |
Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
|
JP5937059B2
(ja)
|
2010-03-22 |
2016-06-22 |
ジェネンテック, インコーポレイテッド |
タンパク質含有製剤の安定化に有用な組成物及び方法
|
CN102958538A
(zh)
*
|
2010-05-03 |
2013-03-06 |
弗·哈夫曼-拉罗切有限公司 |
用于降低含有蛋白质的制剂的粘度的组合物和方法
|
JP2013525491A
(ja)
|
2010-05-04 |
2013-06-20 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
心血管障害を治療または予防し心血管保護を提供する方法
|
AU2011250920B2
(en)
*
|
2010-05-14 |
2015-05-21 |
Amgen Inc. |
High concentration antibody formulations
|
EP2575761A1
(de)
|
2010-05-28 |
2013-04-10 |
Novo Nordisk A/S |
Stabile mehrfachdosiszusammensetzungen mit einem antikörper und einem konservierungsstoff
|
WO2012003470A2
(en)
*
|
2010-07-02 |
2012-01-05 |
Medimmune, Llc |
Antibody formulations
|
KR20190120439A
(ko)
|
2010-11-08 |
2019-10-23 |
제넨테크, 인크. |
피하 투여용 항―il―6 수용체 항체
|
EP2637690B1
(de)
|
2010-11-11 |
2016-09-21 |
AbbVie Biotechnology Ltd |
Anti-tnf-alpha-antikörper-flüssigformulierungen mit hoher konzentration
|
CN105859889B
(zh)
|
2010-11-17 |
2020-01-07 |
中外制药株式会社 |
具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
|
BR112013018740A2
(pt)
|
2011-01-28 |
2019-01-08 |
Sanofi Sa |
anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos
|
US10064987B2
(en)
|
2011-01-31 |
2018-09-04 |
Fresenius Medical Care Holdings, Inc. |
Preventing over-delivery of drug
|
CN106902406B
(zh)
|
2011-02-08 |
2019-11-08 |
弗雷塞尼斯医疗保健控股公司 |
磁性传感器及相关系统和方法
|
EP2681242B1
(de)
|
2011-03-01 |
2018-01-24 |
Amgen Inc. |
Sclerostin- und dkk-1-bispezifische bindemittel
|
PE20140437A1
(es)
|
2011-03-25 |
2014-04-17 |
Amgen Inc |
Formulaciones de anticuerpos
|
AU2012243126A1
(en)
*
|
2011-04-07 |
2013-10-17 |
Glaxosmithkline Llc |
Formulations with reduced viscosity
|
US20140023655A1
(en)
*
|
2011-04-07 |
2014-01-23 |
Glaxosmithkline Llc |
Formulations with reduced viscosity
|
JO3283B1
(ar)
|
2011-04-26 |
2018-09-16 |
Sanofi Sa |
تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
|
EP2736928B1
(de)
|
2011-07-28 |
2019-01-09 |
i2 Pharmaceuticals, Inc. |
Gegen erbb3-gerichtete sur-bindende proteine
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
HUE039786T2
(hu)
|
2011-08-04 |
2019-02-28 |
Amgen Inc |
Csonthiány-defektusok kezelési módszere
|
US9630988B2
(en)
|
2011-09-01 |
2017-04-25 |
Chugai Seiyaku Kabushiki Kaisha |
Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
|
CN103930444B
(zh)
|
2011-09-16 |
2020-08-04 |
瑞泽恩制药公司 |
用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
|
JP6431372B2
(ja)
|
2011-10-25 |
2018-11-28 |
プロシーナ バイオサイエンシーズ リミテッド |
抗体製剤および方法
|
US9364542B2
(en)
*
|
2011-10-28 |
2016-06-14 |
Excelse Bio, Inc. |
Protein formulations containing amino acids
|
EP3091029B1
(de)
|
2011-10-31 |
2022-12-28 |
F. Hoffmann-La Roche AG |
Anti-il13 antikörperformulierungen
|
EP2776052B1
(de)
|
2011-11-02 |
2017-06-14 |
Halscion, Inc. |
Methoden und zusammensetzungen zur wundbehandlung
|
EP2776091B1
(de)
|
2011-11-07 |
2021-03-03 |
Battelle Memorial Institute |
Verfahren für therapien mit abgabe viskoser arzneimittel
|
DK2596796T3
(da)
|
2011-11-24 |
2014-01-27 |
Quimera Ingenieria Biomedica S L |
Kompleks opnået af hyaluronsyre eller et salt deraf samt chondroitinsulfatblandinger
|
ES2710916T3
(es)
|
2011-12-22 |
2019-04-29 |
I2 Pharmaceuticals Inc |
Proteínas de unión sustitutas
|
EP2797953B1
(de)
|
2011-12-28 |
2020-06-03 |
Amgen Inc. |
Verfahren zur behandlung von alveolarknochenverlust durch verwendung von anti-sclerostin-antikörpern
|
WO2013112438A1
(en)
|
2012-01-23 |
2013-08-01 |
Regeneron Pharmaceuticals, Inc. |
Stabilized formulations containing anti-ang2 antibodies
|
US9144646B2
(en)
|
2012-04-25 |
2015-09-29 |
Fresenius Medical Care Holdings, Inc. |
Vial spiking devices and related assemblies and methods
|
SI2849723T1
(sl)
|
2012-05-18 |
2018-09-28 |
Genentech, Inc. |
Formulacije z visoko koncentracijo monoklonskih protiteles
|
AR092325A1
(es)
|
2012-05-31 |
2015-04-15 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
|
EP2859018B1
(de)
|
2012-06-06 |
2021-09-22 |
Zoetis Services LLC |
Anti-ngf-antikörper für hunde und verfahren dafür
|
MX2014014717A
(es)
*
|
2012-06-21 |
2015-03-06 |
Ucb Pharma Sa |
Formulacion farmaceutica.
|
JP6770312B2
(ja)
|
2012-07-05 |
2020-10-14 |
ユセベ ファルマ ソシエテ アノニム |
骨疾患の治療
|
US9221904B2
(en)
|
2012-07-19 |
2015-12-29 |
National Cheng Kung University |
Treatment of osteoarthritis using IL-20 antagonists
|
US8852588B2
(en)
|
2012-08-07 |
2014-10-07 |
National Cheng Kung University |
Treating allergic airway disorders using anti-IL-20 receptor antibodies
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|
FR2994390B1
(fr)
*
|
2012-08-10 |
2014-08-15 |
Adocia |
Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
US8613919B1
(en)
|
2012-08-31 |
2013-12-24 |
Bayer Healthcare, Llc |
High concentration antibody and protein formulations
|
UA115789C2
(uk)
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
JP6463268B2
(ja)
|
2012-09-07 |
2019-01-30 |
コヒラス・バイオサイエンシズ・インコーポレイテッド |
安定水性アダリムマブ製剤
|
FR2995214B1
(fr)
*
|
2012-09-10 |
2014-11-21 |
Adocia |
Solution a viscosite reduite de proteine a concentration elevee
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
US9474803B2
(en)
*
|
2012-11-27 |
2016-10-25 |
Alteogen Inc. |
Composition for stabilizing fusion protein in which protein and FC domain are fused
|
WO2014141149A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Formulations with reduced viscosity
|
EP3508213A1
(de)
|
2013-03-15 |
2019-07-10 |
Shire Viropharma Incorporated |
C1-inh-zusammensetzungen und verfahren zur vorbeugung und behandlung von erkrankungen im zusammenhang mit c1-esterase-inhibitor-defianz
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
BR112015032960B1
(pt)
|
2013-07-04 |
2021-01-05 |
F. Hoffmann-La Roche Ag |
imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro
|
CR20160132A
(es)
|
2013-08-12 |
2016-08-25 |
Genentech Inc |
Composiciones y método para tratar condiciones asociadas con el complemento
|
RU2675824C2
(ru)
|
2013-09-11 |
2018-12-25 |
Игл Байолоджикс, Инк. |
Жидкие белковые составы, содержащие ионные жидкости
|
JP6534615B2
(ja)
|
2013-09-27 |
2019-06-26 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
TWI670077B
(zh)
|
2013-11-12 |
2019-09-01 |
賽諾菲生物技術公司 |
使用pcsk9抑制劑之給藥療程
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
US9034332B1
(en)
|
2014-07-15 |
2015-05-19 |
Kymab Limited |
Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
US8945560B1
(en)
|
2014-07-15 |
2015-02-03 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
US9045548B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
US9051378B1
(en)
|
2014-07-15 |
2015-06-09 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
US8883157B1
(en)
|
2013-12-17 |
2014-11-11 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
US9023359B1
(en)
|
2014-07-15 |
2015-05-05 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
AU2015253042A1
(en)
|
2014-05-01 |
2016-10-20 |
Genentech, Inc. |
Anti-factor D antibody variants and uses thereof
|
US11357857B2
(en)
|
2014-06-20 |
2022-06-14 |
Comera Life Sciences, Inc. |
Excipient compounds for protein processing
|
US10478498B2
(en)
|
2014-06-20 |
2019-11-19 |
Reform Biologics, Llc |
Excipient compounds for biopolymer formulations
|
WO2015196091A1
(en)
*
|
2014-06-20 |
2015-12-23 |
Reform Biologics, Llc |
Viscosity-reducing excipient compounds for protein formulations
|
US9150660B1
(en)
|
2014-07-15 |
2015-10-06 |
Kymab Limited |
Precision Medicine by targeting human NAV1.8 variants for treatment of pain
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
KR20170029613A
(ko)
|
2014-07-16 |
2017-03-15 |
사노피 바이오테크놀로지 |
이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
|
DK3170005T3
(da)
|
2014-07-18 |
2019-07-08 |
Sanofi Sa |
Fremgangsmåde til forudsigelse af resultatet af en behandling med aflibercept hos en patient, der mistænkes for at lide af cancer
|
WO2016019969A1
(en)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
TWI700300B
(zh)
|
2014-09-26 |
2020-08-01 |
日商中外製藥股份有限公司 |
中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體
|
TWI701435B
(zh)
|
2014-09-26 |
2020-08-11 |
日商中外製藥股份有限公司 |
測定fviii的反應性之方法
|
WO2016054259A1
(en)
|
2014-10-01 |
2016-04-07 |
Arsia Therapeutics, Inc. |
Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
|
AR102198A1
(es)
|
2014-10-09 |
2017-02-08 |
Regeneron Pharma |
Proceso para reducir partículas subvisibles en una formulación farmacéutica
|
CN107073113A
(zh)
*
|
2014-10-18 |
2017-08-18 |
辉瑞大药厂 |
抗il‑7r抗体组合物
|
SI3215528T1
(sl)
|
2014-11-06 |
2019-11-29 |
Hoffmann La Roche |
Variante regije Fc s spremenjeno vezavo FcRn in postopki uporabe
|
US9926375B2
(en)
|
2014-11-12 |
2018-03-27 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
US10155820B2
(en)
|
2014-11-12 |
2018-12-18 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
MA41142A
(fr)
|
2014-12-12 |
2017-10-17 |
Amgen Inc |
Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
|
AU2016210918A1
(en)
|
2015-01-28 |
2017-07-13 |
Pfizer Inc., |
Stable aqueous anti- vascular endothelial growth factor (VEGF) antibody formulation
|
AR103726A1
(es)
|
2015-02-27 |
2017-05-31 |
Merck Sharp & Dohme |
Cristales de anticuerpos monoclonales anti-pd-1 humanos
|
JP7082484B2
(ja)
|
2015-04-01 |
2022-06-08 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
JP2018521129A
(ja)
*
|
2015-07-07 |
2018-08-02 |
ナノビオ コーポレイションNanobio Corporation |
タンパク質の安定化のための方法および組成物
|
US11173197B2
(en)
*
|
2015-07-07 |
2021-11-16 |
Bluewillow Biologics, Inc. |
Methods and compositions for nanoemulsion vaccine formulations
|
US20170007690A1
(en)
*
|
2015-07-07 |
2017-01-12 |
Nanobio Corporation |
Methods and compositions for the stabilization of anthrax recombinant protective antigen
|
PL3334747T3
(pl)
|
2015-08-13 |
2024-04-02 |
Amgen Inc. |
Naładowana filtracja wgłębna białek wiążących antygen
|
EP3337828A1
(de)
|
2015-08-18 |
2018-06-27 |
Regeneron Pharmaceuticals, Inc. |
Anti-pcsk9-hemmerantikörper zur behandlung von patienten mit hyperlipidämie, die einer lipoproteinapherese unterzogen werden
|
US11229702B1
(en)
|
2015-10-28 |
2022-01-25 |
Coherus Biosciences, Inc. |
High concentration formulations of adalimumab
|
JP2018534930A
(ja)
|
2015-10-30 |
2018-11-29 |
ジェネンテック, インコーポレイテッド |
抗d因子抗体及びコンジュゲート
|
EP3368090A1
(de)
|
2015-10-30 |
2018-09-05 |
H. Hoffnabb-La Roche Ag |
Anti-faktor-d-antikörpervarianten-konjugate und verwendungen davon
|
AU2016381992B2
(en)
|
2015-12-28 |
2024-01-04 |
Chugai Seiyaku Kabushiki Kaisha |
Method for promoting efficiency of purification of Fc region-containing polypeptide
|
GB201604124D0
(en)
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
US11071782B2
(en)
|
2016-04-20 |
2021-07-27 |
Coherus Biosciences, Inc. |
Method of filling a container with no headspace
|
US20210189006A1
(en)
|
2016-04-28 |
2021-06-24 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing preparation
|
ES2770674T3
(es)
|
2016-06-10 |
2020-07-02 |
Octapharma Ag |
Composición de inmunoglobulinas de alta concentración para aplicaciones farmacéuticas
|
US20190175683A1
(en)
|
2016-08-05 |
2019-06-13 |
Csl Behring Gmbh |
Pharmaceutical formulations of c1 esterase inhibitor
|
EA201990317A1
(ru)
|
2016-08-16 |
2019-07-31 |
Ридженерон Фармасьютикалз, Инк. |
Способы определения количества индивидуальных антител из смеси
|
AU2017325240A1
(en)
|
2016-09-06 |
2019-05-02 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X
|
WO2018075818A1
(en)
|
2016-10-21 |
2018-04-26 |
Amgen Inc. |
Pharmaceutical formulations and methods of making the same
|
US10613063B2
(en)
|
2016-10-25 |
2020-04-07 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for chromatography data analysis
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
MX2019013072A
(es)
|
2017-05-02 |
2019-12-16 |
Merck Sharp & Dohme |
Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
|
US10646569B2
(en)
*
|
2017-05-16 |
2020-05-12 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
MA49947B1
(fr)
|
2017-08-22 |
2023-03-31 |
Biogen Ma Inc |
Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
|
CN111108202A
(zh)
|
2017-09-29 |
2020-05-05 |
中外制药株式会社 |
具有凝血因子viii(fviii)辅因子功能替代活性的多特异性抗原结合分子及含有所述分子作为活性成分的药物制剂
|
WO2019191534A1
(en)
|
2018-03-30 |
2019-10-03 |
Amgen Inc. |
C-terminal antibody variants
|
CN111989121A
(zh)
*
|
2018-04-16 |
2020-11-24 |
默克专利股份有限公司 |
高浓缩蛋白质制剂的粘度降低
|
MX2020011848A
(es)
|
2018-05-10 |
2021-03-29 |
Regeneron Pharma |
Formulaciones que contienen proteína de fusión del receptor de vegf a alta concentración.
|
TW202005694A
(zh)
|
2018-07-02 |
2020-02-01 |
美商里珍納龍藥品有限公司 |
自混合物製備多肽之系統及方法
|
TW202011995A
(zh)
*
|
2018-07-03 |
2020-04-01 |
比利時商葛萊伯格有限公司 |
高濃度液體抗體配製物
|
IL267923B2
(en)
*
|
2018-08-02 |
2023-06-01 |
Grifols Worldwide Operations Ltd |
The composition containing the most concentrated alpha-1 type protein inhibitor and a method for obtaining it
|
WO2021038532A1
(en)
*
|
2019-08-30 |
2021-03-04 |
Kashiv Biosciences, Llc |
Novel formulation of highly concentrated pharmacologically active antibody
|
EP3808777A1
(de)
|
2019-10-16 |
2021-04-21 |
Glenmark Specialty S.A. |
Stabile flüssige antikörperformulierungen
|
AU2021308997A1
(en)
|
2020-07-13 |
2023-02-02 |
Merck Patent Gmbh |
Viscosity reducing excipients and combinations thereof for highly concentrated protein formulations
|
AU2021316017A1
(en)
|
2020-07-31 |
2023-02-16 |
F. Hoffmann-La Roche Ag |
Anti-integrin beta7 antibody formulations and devices
|
WO2023175035A1
(en)
*
|
2022-03-15 |
2023-09-21 |
Adrenomed Ag |
Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment
|